Patents Assigned to Gilead Sciences, Inc.
  • Therapeutic compounds
    Patent number: 10836746
    Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: November 17, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas Brizgys, Eda Canales, Chienhung Chou, Michael Graupe, Jiayao Li, Roland D. Saito, Scott D. Schroeder, Winston C. Tse, Qiaoyin Wu, Jennifer R. Zhang
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 10836825
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: November 17, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 10836769
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: November 17, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: David Alan Gutierrez, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Philip Anthony Morganelli, Hyung-Jung Pyun
  • Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
    Patent number: 10836787
    Abstract: The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate having the structure: for use in treating viral infections. One crystalline form of the compound can be characterized by an X-ray powder diffraction (XRPD) pattern having peaks at 22.3°, 16.9°, and 16.2° 2-?±0.2° 2-?. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: November 17, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Katrien Brak, Ernest A. Carra, Lars V. Heumann, Nate Larson
  • SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR
    Publication number: 20200345738
    Abstract: The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 5, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Sylvie M. Asselin, Pavel R. Badalov, Henry G. Morrison, Christopher S. Regens, Tiago Vieira
  • Therapeutic compounds
    Patent number: 10800772
    Abstract: Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: October 13, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Hongyan Guo, Mingzhe Ji, Haolun Jin, Amy Lee, Ryan McFadden, Michael L. Mitchell, Manuel Munoz, Hyung-Jung Pyun, Lianhong Xu, Hong Yang
  • Compositions and methods of treating HIV
    Patent number: 10786518
    Abstract: The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: September 29, 2020
    Assignees: Janssen Sciences Ireland UC, Gilead Sciences, Inc.
    Inventors: Katia Boven, Goedele De Smedt, Regina Driesen, Dominiek Henrist, Greet Kauwenberghs, Sandeep Mathur, Scott McCallister, Roel Mertens, Richard Nettles, Magda Opsomer, William Pyrz, Vahid Zia
  • HIV protease inhibitors
    Patent number: 10774053
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Aesop Cho, Ana Zurisadai Gonzalez Buenrostro, Xiaochun Han, Salman Y. Jabri, Ryan McFadden, Yingmei Qi, Johannes Voigt, Hong Yang, Jie Xu, Lianhong Xu
  • PD-1/PD-L1 inhibitors
    Patent number: 10774071
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • FXR (NR1H4) modulating compounds
    Patent number: 10774054
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • HIV inhibitor compounds
    Patent number: 10752636
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: August 25, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Processes for preparing ACC inhibitors and solid forms thereof
    Patent number: 10745412
    Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: August 18, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Luke Humphreys, Mark E. Scott
  • ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
    Publication number: 20200223907
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 16, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • PD-1/PD-L1 inhibitors
    Patent number: 10710986
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 14, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • MCL-1 inhibitors
    Patent number: 10703733
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 7, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Methods and compounds for treating paramyxoviridae virus infections
    Patent number: 10696679
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
  • Methods for treating arenaviridae and coronaviridae virus infections
    Patent number: 10695361
    Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel
  • Methods and intermediates for preparing therapeutic compounds
    Patent number: 10696657
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 30, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Amanda L. Vandehey, Gediminas Brizgys, Vinh X. Ngo, Brian M. O'Keefe, Trevor J. Rainey, Bing Shi, Winston C. Tse, Anna M. Wagner, Xianghong Wang, Scott A. Wolckenhauer, Chloe Y. Wong
  • Methods for treating filoviridae virus infections
    Patent number: 10695357
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Byoung Kwon Chun, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: RE48150
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, R, R1, R2 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: August 11, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Gregory Notte, Jeff Zablocki